Emily A. Liu

4.9k total citations · 1 hit paper
5 papers, 3.9k citations indexed

About

Emily A. Liu is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Emily A. Liu has authored 5 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Genetics, 2 papers in Pathology and Forensic Medicine and 1 paper in Molecular Biology. Recurrent topics in Emily A. Liu's work include Chronic Lymphocytic Leukemia Research (3 papers), Lymphoma Diagnosis and Treatment (2 papers) and Gastrointestinal Tumor Research and Treatment (1 paper). Emily A. Liu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Lymphoma Diagnosis and Treatment (2 papers) and Gastrointestinal Tumor Research and Treatment (1 paper). Emily A. Liu collaborates with scholars based in United States and Germany. Emily A. Liu's co-authors include Frank Podlaski, Christine Lukacs, Nader Fotouhi, Christian Klein, Zoran Filipovic, Norman Kong, U. Kammlott, Bradford Graves, Daisy Carvajal and Binh Thanh Vu and has published in prestigious journals such as Science, Blood and Clinical Cancer Research.

In The Last Decade

Emily A. Liu

5 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

2004 3.7k citations Lyubomir T. Vassilev, Binh Thanh Vu et al. Science profile →

Peers

Countries citing papers authored by Emily A. Liu

Since Specialization

Citations

This map shows the geographic impact of Emily A. Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily A. Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily A. Liu more than expected).

Fields of papers citing papers by Emily A. Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily A. Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily A. Liu. The network helps show where Emily A. Liu may publish in the future.

Co-authorship network of co-authors of Emily A. Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Emily A. Liu. A scholar is included among the top collaborators of Emily A. Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily A. Liu. Emily A. Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study 2020 ·Clinical Cancer Research ·John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien	126
2	Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma 2019 ·American Journal of Hematology ·Alex F. Herrera, André Goy, Amitkumar Mehta, Radhakrishnan Ramchandren, John M. Pagel, Jakub Svoboda, (unknown), (unknown), Kevin Kwei, Emily A. Liu, Tycel Phillips	47
3	Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2018 ·Blood ·John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien	13
4	Improved Time to Progression for Transarterial Chemoembolization Compared With Transarterial Embolization for Patients With Unresectable Hepatocellular Carcinoma 2012 ·Clinical Colorectal Cancer ·Michael A. Morse, Brent A. Hanks, Paul V. Suhocki, Phuong L. Doan, Emily A. Liu, (unknown), Stephen A. Bernard, (unknown), Dominic T. Moore, Bert H. O’Neil	14
5	In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 breakdown → 2004 ·Science ·Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves, Daisy Carvajal, Frank Podlaski, Zoran Filipovic, Norman Kong, U. Kammlott, Christine Lukacs, Christian Klein, Nader Fotouhi, Emily A. Liu	3722

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact